Critical reviews in oncology/hematology最新文献

{"title":"Nano-omics and nanomedicine target microbial carcinogenesis: Tumor microenvironment reprograming to clinical translation","authors":"Vincent Kawuribi ,&nbsp;Yiyang Xie ,&nbsp;Haiqing Xu ,&nbsp;Yingchun Zhang ,&nbsp;Shaohui Zheng","doi":"10.1016/j.critrevonc.2025.104866","DOIUrl":"10.1016/j.critrevonc.2025.104866","url":null,"abstract":"<div><div>Microbial infections are implicated in a significant fraction of human cancers, with specific bacterial, viral, and parasitic pathogens known to drive oncogenesis via chronic inflammation, genotoxic metabolites, and immune evasion. This review clarifies the major microbial players (e.g. <em>Helicobacter pylori</em>, HPV, HBV, <em>Fusobacterium nucleatum</em>, schistosomes) and their carcinogenic mechanisms, with an emphasis on how these alter the tumour microenvironment (TME). We then discuss nano-enabled strategies that target microbe-associated tumours, including targeted nano-therapies against <em>H. pylori</em> and <em>F. nucleatum</em>, nanoparticle vaccines against viral oncoproteins (e.g. HPV E6/E7), and “nano-omics” tools for tumour microbiota profiling. Next, we expand on the roles of nanomedicine in modulating the microbiota-modified immune TME (TIME): nanoparticles can reprogram tumour-associated macrophages (TAMs), activate dendritic cells, and combine with immune checkpoint inhibitors to overcome microbial immunosuppression. Mechanistic diagrams (e.g. nanoparticle-driven TAM repolarization and immunogenic cell death) illustrate these effects. Finally, we examine theranostic and smart delivery systems that integrate imaging and therapy: examples include stimuli-responsive nanocarriers releasing drugs in response to tumour acidity or enzymes, and hybrid liposome-based nanoparticles enabling simultaneous cancer imaging and treatment. Throughout, analytical commentary highlights how these nano-approaches synergize to counteract microbial carcinogenesis and reprogram the TME. This comprehensive review synthesizes the latest research (2010–2025) and offers critical interpretation of future clinical translation opportunities.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"213 ","pages":"Article 104866"},"PeriodicalIF":5.6,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety assessment of antibody-drug conjugates: Nonclinical toxicology, non-active ingredients, and environmental risk considerations","authors":"Frank Liu","doi":"10.1016/j.critrevonc.2025.104865","DOIUrl":"10.1016/j.critrevonc.2025.104865","url":null,"abstract":"<div><div>Antibody-drug conjugates (ADCs) have become one of the most rapidly growing drug modalities for cancer treatment. By May 2025, US FDA has approved fifteen ADCs treating various types of cancer. Due to their triplex structure, their safety assessment is challenging compared with small molecules and monoclonal antibodies. In regulatory submissions of drug products (DPs), various safety aspects, such as nonclinical toxicology, assessment of excipients and impurities, and environmental risk must be included. Currently, an ICH guideline specific to ADCs is not available for their nonclinical toxicological studies. Beyond active pharmaceutical ingredients (APIs), excipients and impurities are critical aspects for ADCs. When ADCs and their components are released into the environment, they may pose environmental risk. Assessment must be performed to evaluate safety of ADCs from these aspects. However, they are challenging to perform because of the unique structure and lack of the current guideline from health agencies specific to ADCs. The paper reviews the current status of the regulations and safety assessment practice of nonclinical, excipients, impurities, and environmental risk of ADCs. It is expected that the learning from and holistic understanding of the retrospective development of the ADCs, as presented in the current review, will empower further expansion of ADCs to new therapeutic areas and enable more effective development of ADCs.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"215 ","pages":"Article 104865"},"PeriodicalIF":5.6,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards a new approach in pleural mesothelioma: Perioperative immunotherapy and its implications","authors":"Paolo Ambrosini ,&nbsp;Alessia Stanzi ,&nbsp;Giuseppe Lo Russo ,&nbsp;Piergiorgio Solli ,&nbsp;Mario Occhipinti","doi":"10.1016/j.critrevonc.2025.104864","DOIUrl":"10.1016/j.critrevonc.2025.104864","url":null,"abstract":"<div><div>Pleural mesothelioma is a rare malignancy that has historically had a poor prognosis, even with systemic chemotherapy. Although immune checkpoint inhibitors have improved survival rates for patients with advanced, unresectable disease, their role in perioperative management is unclear. We conducted a review of early-phase trials and case series examining the use of immune checkpoint blockade alone or in combination with platinum-based chemotherapy and surgery for pleural mesothelioma. We then contrasted these findings with established perioperative immunotherapy paradigms in non-small cell lung cancer. For pleural mesothelioma, feasibility studies have reported a major pathological response in up to 25 % of patients, a median progression-free survival of 14–19 months and sporadic instances of a pathological complete response. These studies have also reported acceptable toxicity and surgical timings. In contrast, non-small cell lung cancer trials have demonstrated consistent major pathological response rates of over 50 %, significant event-free survival benefits and validated complete response endpoints. These divergent outcomes reflect differences in tumor microenvironment, mutational burden, histological subtypes and predictive biomarkers between the two diseases. Our analysis highlights the need for standardized pathological endpoints, refined patient selection criteria and larger randomized studies to optimize the sequencing and combination of immunotherapy, chemotherapy and surgery in pleural mesothelioma. Such efforts are essential for integrating perioperative immune strategies into multimodal care and improving long-term outcomes.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"215 ","pages":"Article 104864"},"PeriodicalIF":5.6,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging biomarkers in bladder cancer: Translating molecular advances into precision oncology","authors":"Matteo Ferro ,&nbsp;Felice Crocetto ,&nbsp;Letizia Maria Ippolita Jannello ,&nbsp;Roberto Contieri ,&nbsp;Ugo Giovanni Falagario ,&nbsp;Alessandro Veccia ,&nbsp;Michele Marchioni ,&nbsp;Sabin Octavian Tataru ,&nbsp;Biagio Barone ,&nbsp;Giuseppe Fallara ,&nbsp;Marco Tozzi ,&nbsp;Francesco Chierigo ,&nbsp;Martina Maggi ,&nbsp;Roberto Bianchi ,&nbsp;Francesco Pellegrino ,&nbsp;Bernardo Maria Cesare Rocco ,&nbsp;Vartolomei Mihai Dorin ,&nbsp;Daniela Terracciano","doi":"10.1016/j.critrevonc.2025.104862","DOIUrl":"10.1016/j.critrevonc.2025.104862","url":null,"abstract":"<div><div>Bladder cancer (BC) is a heterogeneous malignancy of the urinary tract with significant clinical challenges in diagnosis, prognosis, and treatment. The rise of precision medicine offers new hope for more personalized management, driven by biomarker discovery and molecular profiling. This review explores the landscape of emerging biomarkers in BC, discussing in detail diagnostic, prognostic, and predictive implications in the present and further scenarios for improving clinical management of BC patients. An in-depth analysis of the current literature was conducted, with attention to genomic (e.g., <em>FGFR3, TP53, ERBB2</em>), epigenetic (DNA methylation, non-coding RNAs), transcriptomic (molecular subtypes and RNA signatures), proteomic, and immunological biomarkers (PD-L1, TMB, MSI). Multiple biomarkers are already influencing clinical decision-making, such as FGFR-targeted therapy in patients with <em>FGFR3</em> mutations and immune checkpoint inhibitors (ICI) in PD-L1-expressing tumors. Molecular subtyping enables stratification of muscular-invasive BC into luminal, basal, and neuroendocrine-like subtypes with distinct therapeutic implications. Urinary and blood-based biomarkers show promise for non-invasive monitoring, though challenges remain in clinical validation. Biomarkers are central to the transition from empirical to personalized care in BC. While several markers are already clinically actionable, future implementation will depend on overcoming technical, regulatory, and economic barriers. Integrating genomic, transcriptomic, and immunological data, supported by artificial intelligence and digital pathology, will be key to unlocking the full potential of precision medicine in urothelial carcinoma.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"215 ","pages":"Article 104862"},"PeriodicalIF":5.6,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of JAK/STAT signaling on anti-PD-L1 immunotherapy efficacy in lung cancer","authors":"Yaji Yao,&nbsp;Gang Tao,&nbsp;Dongyu Xie,&nbsp;Yuetao Xu,&nbsp;Liang Li","doi":"10.1016/j.critrevonc.2025.104861","DOIUrl":"10.1016/j.critrevonc.2025.104861","url":null,"abstract":"<div><div>Lung cancer remains the leading cause of cancer-related mortality worldwide, with advanced-stage non-small cell lung cancer (NSCLC) patients often showing limited responses to immunotherapies, notably those targeting the PD-1/PD-L1 axis. This study aimed to elucidate the role of the JAK/STAT signaling pathway in modulating PD-L1 expression and its impact on the efficacy of anti-PD-L1 immunotherapy in lung cancer. By comprehensively reviewing molecular mechanisms and recent experimental evidence, we investigated how aberrant JAK/STAT activation, through genetic alterations, cytokine-mediated signals, and environmental influences, drives PD-L1 upregulation and contributes to an immunosuppressive tumor microenvironment. Our findings reveal that enhanced JAK/STAT signaling facilitates immune evasion by promoting transcriptional activation of PD-L1 and supporting oncogenic processes such as cell proliferation, survival, and metastasis. Conversely, impaired JAK/STAT function can diminish PD-L1 expression, thereby altering the sensitivity of tumor cells to checkpoint blockade. Importantly, preclinical studies highlighted the potential of combination therapeutic strategies that target both the JAK/STAT pathway and PD-L1 to restore effective T cell responses and overcome resistance to immunotherapy. These insights underscore the need for tailored treatment approaches that integrate JAK/STAT inhibitors with PD-L1 blockade, potentially paving the way for improved clinical outcomes in lung cancer patients.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"214 ","pages":"Article 104861"},"PeriodicalIF":5.6,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144710313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic reprogramming of NK cells drives anti-tumor immunity","authors":"Pengcheng Yang ,&nbsp;Wanrong Wang ,&nbsp;Qiuyu Liu ,&nbsp;Siqi Mu ,&nbsp;Yue Zha ,&nbsp;Weizhen Yan ,&nbsp;Bin Yuan ,&nbsp;Jing Yang","doi":"10.1016/j.critrevonc.2025.104859","DOIUrl":"10.1016/j.critrevonc.2025.104859","url":null,"abstract":"<div><div>Cellular metabolism critically controls immune cell functionality, necessitating dynamic metabolic adaptation to sustain effector responses under microenvironmental fluctuations. Natural killer (NK) cells, innate lymphocytes essential for tumor immunosurveillance, exhibit functional plasticity intrinsically linked to metabolic reprogramming. While NK cell-based immunotherapy show promise due to MHC-independent cytotoxic, their clinical efficacy diverges markedly between hematological and solid tumor-a disparity rooted in tumor microenvironment (TME) driven immunosuppression. Cancer cells subvert NK cell elimination through metabolic competition, creating nutrient-depleted milieus that impair mitochondrial bioenergetics and glycolytic flux in tumor-infiltrating NK populations. These constraints induce functional exhaustion, characterized by diminished cytokine production and cytotoxic granule release, facilitating immune evasion. Emerging strategies targeting metabolic checkpoints—including glucose utilization, amino acid metabolism, and lipid signaling—demonstrate capacity to restore NK cell metabolic fitness. Preclinical models reveal enhanced anti-tumor activity when combining metabolic modulators with cytokine priming or checkpoint inhibitors, establishing metabolic optimization as a biochemical framework to overcome TME limitations. These advances position NK cell metabolic engineering as a promising approach for next-generation solid tumor immunotherapies, driving translational research toward precision metabolic reprogramming strategies.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"215 ","pages":"Article 104859"},"PeriodicalIF":5.5,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of the SIX family in cancer development and therapy: Insights from foundational and cutting-edge research","authors":"Shiyu Huang ,&nbsp;Yujie Chen ,&nbsp;Min Hu ,&nbsp;Shujie Fu ,&nbsp;Zhiyuan Yao ,&nbsp;Hao He ,&nbsp;Lei Wang ,&nbsp;Zhiyuan Chen ,&nbsp;Xiuheng Liu","doi":"10.1016/j.critrevonc.2025.104860","DOIUrl":"10.1016/j.critrevonc.2025.104860","url":null,"abstract":"<div><div>The SIX (Sine Oculis homeobox) gene family plays a crucial role in carcinogenesis and cancer therapy by encoding transcription factors that regulate a diverse array of downstream target genes through mechanisms of repression and activation. This review, founded on existing research and incorporating bioinformatics tools, summarizes the expression patterns, prognostic significance, functional roles, and underlying mechanisms of the SIX family across various tumor types. Additionally, it explores the impact of the SIX family in multiple cancer treatment approaches, including cancer chemotherapy, radiotherapy, targeted therapy, immunotherapy, and herbal or natural ingredient therapy. In essence, this review provides a comprehensive overview of the significant role of the SIX family in tumor development, serving as a valuable resource for further studies.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"214 ","pages":"Article 104860"},"PeriodicalIF":5.6,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk assessment and interventions for malignant ground-glass lung nodules","authors":"Xinyue Ge ,&nbsp;Jiaqi Hu ,&nbsp;Yue Li ,&nbsp;Linfeng Wang ,&nbsp;Yue Luo ,&nbsp;Baojin Hua ,&nbsp;Rui Liu","doi":"10.1016/j.critrevonc.2025.104856","DOIUrl":"10.1016/j.critrevonc.2025.104856","url":null,"abstract":"<div><div>Pulmonary ground-glass nodules (GGNs) have become a major problem owing to their high frequency, limited diagnostic differentiation, complex pathogenesis, and lack of effective intervention strategies. With the ongoing increase in the frequency of pulmonary nodules and improved control of smoking, GGNs may become the predominant manifestation of early-stage lung cancer (LC) in the future. However, current diagnostic approaches are limited in terms of both accuracy and specificity, leading to a dual challenge of overtreatment and delayed intervention. The present review briefly summarizes the most recent research on the scientific and clinical dimensions of early diagnosis and treatment for malignant GGNs. We summarize key population characteristics, imaging features, imaging pathological analysis, and biomarkers, encompassing genetic alterations, RNA, circulating tumor DNA, DNA methylation, autoantibodies, proteins, metabolites, the microbiome, circulating tumor cells, blood parameters, angiogenic markers, volatile biomarkers, and reactive oxygen species indicators. Additionally, we assess predictive models, recent and potential therapeutic strategies, artificial intelligence studies, and discuss intrinsic biological mechanisms, while highlighting key challenges in LC diagnosis and treatment. This review highlights that novel technologies and multidisciplinary approaches hold considerable potential in advancing precise early diagnosis, which is critical for reducing LC incidence.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"215 ","pages":"Article 104856"},"PeriodicalIF":5.5,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibody-oligonucleotide conjugates in cancer therapy: Potential and Promise","authors":"Qinghe Meng ,&nbsp;Mo Yang ,&nbsp;Fei Xing ,&nbsp;Zhenxia Xie ,&nbsp;Yimeng Hao ,&nbsp;Ping Jiang ,&nbsp;Baiquan Xiao","doi":"10.1016/j.critrevonc.2025.104858","DOIUrl":"10.1016/j.critrevonc.2025.104858","url":null,"abstract":"<div><div>X-Drug Conjugates (XDCs) achieve precise therapy through a modular design comprising three key components: targeting vehicle, linker, and therapeutic payload. Among these, Antibody-Drug Conjugate (ADCs) have demonstrated the most remarkable progress in clinical research. By leveraging their precise targeting mechanism and robust clinical data, ADCs have emerged as frontrunner therapeutics in oncology. Building upon this success, Antibody-Oligonucleotide Conjugates (AOCs) represent an innovative evolution—replacing traditional cytotoxic payloads with gene-modulating oligonucleotides, such as small interfering RNA (siRNA) and antisense oligonucleotides (ASO). This paradigm shift transitions the therapeutic focus from \"cell killing\" to \"gene regulation\", opening new avenues for cancer treatment. In this review, we provide an overview of the biology and chemistry of AOCs, examine the key components of AOC design (including the antibody, linker and conjugation chemistry, and oligonucleotides, and highlight promising AOC candidates currently in clinical development for cancer treatment while evaluating both the challenges and opportunities. By discussing recent advances in AOCs, we offer valuable insights into future directions for this innovative class of immunoconjugates and their potential to revolutionize targeted cancer therapies.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"215 ","pages":"Article 104858"},"PeriodicalIF":5.5,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel androgen receptor inhibitors in prostate cancer: What do we know so far?","authors":"Francesca Rifaldi ,&nbsp;Anna Tortorella ,&nbsp;Silvio Sporeni ,&nbsp;Irene Lanzetta ,&nbsp;Simone Figini ,&nbsp;Richard Lawrence John Naspro ,&nbsp;Andrea Lancia ,&nbsp;Benedetta Montagna ,&nbsp;Simona Secondino ,&nbsp;Paolo Pedrazzoli ,&nbsp;Silvia Chiellino","doi":"10.1016/j.critrevonc.2025.104857","DOIUrl":"10.1016/j.critrevonc.2025.104857","url":null,"abstract":"<div><div>Prostate cancer (PC) is the second most common cancer among males, following lung cancer, more frequently occurring at an advanced age. Even nowadays, early diagnosis represents a challenge and validated screening methods are still missing. To date, multiple therapeutic strategies are available and a tailored approach is possible. The backbone of PC therapy is represented by the inhibition of the androgen signaling pathway, which mediates tumor cells growth. In this current therapeutic scenario, androgen-receptors signaling inhibitors (ARSIs) play a role in improving cancer treatment. This paper provides an overview of the currently available treatment options, focusing on the new drugs (ARSIs), their actual implications and future developments.</div></div><div><h3>Methods</h3><div>We conducted a research from Pubmed and Embase database regarding the terms ‘prostate cancer’, ‘ARSI’, ‘androgen receptor inhibitors’, ‘’enzalutamide”, “apalutamide”, and “Darolutamide”. Original full-text articles published in English were reviewed. Based on this research 185 potentially relevant articles were found, limiting our research to the period 2019–2025 of publication. 75 articles were excluded on the basis of abstract, title or the content.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"215 ","pages":"Article 104857"},"PeriodicalIF":5.6,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}